STAT

Opinion: The White House’s about-face on drug rebates is a loss for public health

None of the $166 billion in discounts that pharmacy benefit managers get from pharmaceutical companies is used to reduce patients' out-of-pocket costs when they need medicines.
Source: BRENDAN SMIALOWSKI/AFP/Getty Images

Even in the complicated ecosystem of drug pricing, one fact stands out: $166 billion in discounts from pharmaceutical companies go directly into the coffers of pharmacy benefit managers. That’s 37% of our nation’s entire expense on drugs.

Not a single dollar of that largesse is used to reduce patients’ out-of-pocket costs when they need medicines. So when the White House to change the dynamic by banning many rebates drug companies pay to pharmacy benefit managers under Medicare, policy experts applauded. That, the victim of intense lobbying and general ignorance. Who loses? Patients. Who wins? The status quo.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: IVF Doctors Demand Full Details On Fluid That Grows Embryos Amid CooperSurgical Lawsuits
Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos. The fluid, called culture media, is filled with nutrie
STAT1 min read
Disparities In Donor Acceptance Rates Point To Need For More Equitable Heart Transplant Care
While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.
STAT1 min read
STAT+: AstraZeneca Sues Arkansas Over The Role Of Pharmacies In A Federal Discount Drug Program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a federal discount program.

Related Books & Audiobooks